PIM inhibitors have shown in vitro activity through both Myc-dependent and Myc-independent pathways against numerous tumour cell lines ranging from haematological tumours to breast and prostate cancer [31,177,178,211,214,215], but their results in clinical studies are often disappointing. The gene discussed is MYC; the disease is prostate carcinoma.